JP2016505512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505512A5 JP2016505512A5 JP2015539801A JP2015539801A JP2016505512A5 JP 2016505512 A5 JP2016505512 A5 JP 2016505512A5 JP 2015539801 A JP2015539801 A JP 2015539801A JP 2015539801 A JP2015539801 A JP 2015539801A JP 2016505512 A5 JP2016505512 A5 JP 2016505512A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- lower alkyl
- pde4
- cyano
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 18
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 18
- -1 trifluoromethoxy, hydroxyl Chemical group 0.000 claims 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 230000001404 mediated effect Effects 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- XOQABDOICLHPIS-UHFFFAOYSA-N 1-hydroxy-2,1-benzoxaborole Chemical compound C1=CC=C2B(O)OCC2=C1 XOQABDOICLHPIS-UHFFFAOYSA-N 0.000 claims 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 6
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 claims 6
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 claims 6
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 claims 6
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 claims 6
- 230000006870 function Effects 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 230000003920 cognitive function Effects 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718285P | 2012-10-25 | 2012-10-25 | |
| US61/718,285 | 2012-10-25 | ||
| US201261733675P | 2012-12-05 | 2012-12-05 | |
| US61/733,675 | 2012-12-05 | ||
| US201361776937P | 2013-03-12 | 2013-03-12 | |
| US61/776,937 | 2013-03-12 | ||
| PCT/US2013/066645 WO2014066659A1 (en) | 2012-10-25 | 2013-10-24 | Heteroaryl inhibitors of pde4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505512A JP2016505512A (ja) | 2016-02-25 |
| JP2016505512A5 true JP2016505512A5 (enExample) | 2016-12-15 |
| JP6289485B2 JP6289485B2 (ja) | 2018-03-07 |
Family
ID=50545269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539801A Active JP6289485B2 (ja) | 2012-10-25 | 2013-10-24 | Ｐｄｅ４のヘテロアリール阻害剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9221843B2 (enExample) |
| EP (2) | EP3842420B1 (enExample) |
| JP (1) | JP6289485B2 (enExample) |
| KR (1) | KR102189560B1 (enExample) |
| CN (1) | CN104768932B (enExample) |
| AU (1) | AU2013334236B2 (enExample) |
| BR (1) | BR112015009168B1 (enExample) |
| CA (1) | CA2886263C (enExample) |
| CL (1) | CL2015001068A1 (enExample) |
| DK (1) | DK2912019T3 (enExample) |
| ES (1) | ES2871821T3 (enExample) |
| HR (1) | HRP20230162T1 (enExample) |
| HU (1) | HUE056251T2 (enExample) |
| IL (1) | IL238409A (enExample) |
| LT (1) | LT3842420T (enExample) |
| MX (1) | MX368959B (enExample) |
| NZ (1) | NZ705881A (enExample) |
| PL (1) | PL2912019T3 (enExample) |
| PT (1) | PT2912019T (enExample) |
| SG (1) | SG11201502050XA (enExample) |
| SI (1) | SI3842420T1 (enExample) |
| WO (1) | WO2014066659A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| WO2014066659A1 (en) | 2012-10-25 | 2014-05-01 | Tetra Discovery Partners, Llc. | Heteroaryl inhibitors of pde4 |
| MX2015009678A (es) * | 2013-02-04 | 2015-11-25 | Gruenenthal Gmbh | Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4). |
| JP6307525B2 (ja) * | 2013-02-04 | 2018-04-04 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 新規の置換縮合ピリミジン化合物 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| EP3468561A4 (en) | 2016-06-10 | 2019-12-04 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| US11365204B2 (en) | 2017-09-20 | 2022-06-21 | UNION therapeutics A/S | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
| WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2019115774A1 (en) | 2017-12-15 | 2019-06-20 | Leo Pharma A/S | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
| WO2019115776A1 (en) | 2017-12-15 | 2019-06-20 | Leo Pharma A/S | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CA3135420A1 (en) * | 2018-04-05 | 2019-10-10 | Universiteit Hasselt | Selective pde4d inhibitors against demyelinating diseases |
| CN108997394A (zh) * | 2018-06-12 | 2018-12-14 | 广州百霆医药科技有限公司 | 苯并氧杂硼杂环戊烷类化合物及其制备方法 |
| TW202024093A (zh) | 2018-09-21 | 2020-07-01 | 美商安塔製藥公司 | 作為抗病毒劑之官能化雜環 |
| KR102576125B1 (ko) * | 2018-10-05 | 2023-09-08 | 화이자 인코포레이티드 | 붕소 함유 pde4 억제제 |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| CN111635400A (zh) | 2019-03-02 | 2020-09-08 | 察略盛医药科技(上海)有限公司 | 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 |
| WO2020214874A1 (en) * | 2019-04-18 | 2020-10-22 | Tetra Discovery Partners, Inc. | Salts and polymorphs of a pde4 inhibitor |
| EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| EP3994142A4 (en) | 2019-07-03 | 2023-09-06 | Borah, Inc. | CHEMICAL COMPOUNDS |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114149410B (zh) * | 2020-09-07 | 2025-02-25 | 四川科伦博泰生物医药股份有限公司 | 吡啶并环类化合物及其制备方法和用途 |
| US20240116856A1 (en) * | 2020-11-05 | 2024-04-11 | Young Biopharma, Llc | Novel capsaicin analogs and uses thereof |
| EP4748445A3 (en) * | 2020-12-25 | 2026-06-03 | Reistone Biopharma Company Limited | Borate derivative and uses thereof |
| CN115521946B (zh) * | 2022-10-14 | 2024-06-21 | 浙江玖世生物科技有限公司 | 一种TiOx基光酶催化剂合成(R)-1-[3,5-二(三氟甲基)]苯乙醇的方法 |
| JPWO2024135840A1 (enExample) * | 2022-12-23 | 2024-06-27 | ||
| CN118871444A (zh) * | 2023-02-28 | 2024-10-29 | 上海翊石医药科技有限公司 | 二氢噻吩并嘧啶衍生物的制备方法和用途 |
| EP4678644A1 (en) | 2023-04-13 | 2026-01-14 | Shanghai Yidi Biotechnology Co., Ltd. | Substituted dihydrothienopyrimidine compound, preparation method therefor, and use thereof |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
| CN122421966A (zh) | 2023-10-12 | 2026-07-17 | 傲拓神经科学公司 | 用替伐普兰治疗神经精神病症 |
| CN120398908A (zh) * | 2024-02-01 | 2025-08-01 | 艾派克斯生物科技有限公司 | Pde4b抑制剂及其药物组合物和用途 |
| WO2025221488A1 (en) | 2024-04-16 | 2025-10-23 | Alto Neuroscience, Inc. | Transdermal administration of pde4 inhibitors for reduction in adverse events |
| WO2025240378A1 (en) * | 2024-05-13 | 2025-11-20 | Board Of Regents Of The University Of Nebraska | Inhibitors of phosphodiesterases |
| KR20260015118A (ko) * | 2024-07-24 | 2026-02-02 | 제일약품주식회사 | 디하이드로티오피라노피리미딘 화합물 및 이의 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK23392D0 (da) | 1992-02-24 | 1992-02-24 | Novo Nordisk As | Heterocykliske forbindelser, deres anvendelse og fremstilling |
| FR2754260B1 (fr) | 1996-10-04 | 1998-10-30 | Adir | Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU5648599A (en) * | 1998-09-11 | 2000-04-03 | Kyorin Pharmaceutical Co. Ltd. | Phosphonic ester derivatives and process for producing the same |
| ATE368657T1 (de) | 2002-03-08 | 2007-08-15 | Lilly Co Eli | Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren |
| US20050014767A1 (en) | 2003-01-29 | 2005-01-20 | Magnus Pfahl | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
| JP2006123639A (ja) | 2004-10-27 | 2006-05-18 | Mitsubishi Electric Corp | ホームドア状態認識システム |
| WO2006123639A1 (ja) * | 2005-05-18 | 2006-11-23 | Asahi Kasei Pharma Corporation | ピリミジン誘導体 |
| US20060293343A1 (en) * | 2005-05-18 | 2006-12-28 | Asahi Kasei Pharma Corporation | Pyrimidine derivatives |
| US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| WO2009146388A1 (en) | 2008-05-28 | 2009-12-03 | The Trustees Of Columbia University In The City Of New York | Voxel-based methods for assessing subjects using positron emission tomography |
| WO2010027975A1 (en) * | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| RU2380890C1 (ru) | 2008-10-17 | 2010-02-10 | Государственное образовательное учреждение высшего профессионального образования Марийский государственный технический университет | Способ испытания травяного покрова на прирусловой пойме реки |
| WO2010059838A2 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| JP2012519160A (ja) * | 2009-02-27 | 2012-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する組み合わせ薬 |
| EP2380890A1 (en) * | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| WO2014066659A1 (en) * | 2012-10-25 | 2014-05-01 | Tetra Discovery Partners, Llc. | Heteroaryl inhibitors of pde4 |
| JP6307525B2 (ja) * | 2013-02-04 | 2018-04-04 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 新規の置換縮合ピリミジン化合物 |
| WO2015048407A1 (en) | 2013-09-26 | 2015-04-02 | Tetra Discovery Partners, LLC | Heteroaryl inhibitors of pde4 |
| WO2016049595A1 (en) | 2014-09-26 | 2016-03-31 | Tetra Discovery Partners, LLC | Heteroaryl inhibitors of pde4 |
| WO2020214874A1 (en) * | 2019-04-18 | 2020-10-22 | Tetra Discovery Partners, Inc. | Salts and polymorphs of a pde4 inhibitor |
-
2013
- 2013-10-24 WO PCT/US2013/066645 patent/WO2014066659A1/en not_active Ceased
- 2013-10-24 JP JP2015539801A patent/JP6289485B2/ja active Active
- 2013-10-24 US US14/349,688 patent/US9221843B2/en active Active
- 2013-10-24 SI SI201332034T patent/SI3842420T1/sl unknown
- 2013-10-24 HU HUE13848739A patent/HUE056251T2/hu unknown
- 2013-10-24 LT LTEP21156065.1T patent/LT3842420T/lt unknown
- 2013-10-24 PT PT138487392T patent/PT2912019T/pt unknown
- 2013-10-24 MX MX2015005015A patent/MX368959B/es active IP Right Grant
- 2013-10-24 DK DK13848739.2T patent/DK2912019T3/da active
- 2013-10-24 SG SG11201502050XA patent/SG11201502050XA/en unknown
- 2013-10-24 ES ES13848739T patent/ES2871821T3/es active Active
- 2013-10-24 NZ NZ705881A patent/NZ705881A/en unknown
- 2013-10-24 EP EP21156065.1A patent/EP3842420B1/en active Active
- 2013-10-24 HR HRP20230162TT patent/HRP20230162T1/hr unknown
- 2013-10-24 CA CA2886263A patent/CA2886263C/en active Active
- 2013-10-24 BR BR112015009168-7A patent/BR112015009168B1/pt active IP Right Grant
- 2013-10-24 CN CN201380055959.9A patent/CN104768932B/zh active Active
- 2013-10-24 EP EP13848739.2A patent/EP2912019B1/en active Active
- 2013-10-24 AU AU2013334236A patent/AU2013334236B2/en active Active
- 2013-10-24 PL PL13848739T patent/PL2912019T3/pl unknown
- 2013-10-24 KR KR1020157010502A patent/KR102189560B1/ko active Active
-
2015
- 2015-04-21 IL IL238409A patent/IL238409A/en active IP Right Grant
- 2015-04-24 CL CL2015001068A patent/CL2015001068A1/es unknown
- 2015-11-11 US US14/938,544 patent/US9777024B2/en active Active
-
2017
- 2017-08-18 US US15/680,842 patent/US10093686B2/en active Active
-
2018
- 2018-08-24 US US16/111,700 patent/US10364258B2/en active Active
-
2019
- 2019-04-26 US US16/396,457 patent/US10626129B2/en active Active
-
2020
- 2020-02-04 US US16/781,748 patent/US11401286B2/en active Active
-
2022
- 2022-06-23 US US17/808,439 patent/US11767334B2/en active Active
-
2023
- 2023-07-11 US US18/350,452 patent/US12264169B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524883A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| NZ705881A (en) | Heteroaryl inhibitors of pde4 | |
| JP2015505296A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2013528600A5 (enExample) | ||
| JP2018524390A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| JP2011529054A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2016512520A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2017519754A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2015504091A5 (enExample) |